Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2013.08.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploration of Clozapine-Induced Cardiomyopathy and Its Mechanism.
Cardiovasc Toxicol
November 2024
Department of Forensic Medicine, College of Basic Medicine, Chongqing Medical University, Medical College Road, Yuzhong District, Chongqing, China.
Article Synopsis
- The study found that long-term use of the medication clozapine can result in cardiomyopathy, which is similar to a condition called arrhythmogenic cardiomyopathy (ACM), primarily affecting the heart's right ventricle.
- Researchers analyzed the heart tissue of patients who died after prolonged clozapine use and conducted experiments on rat heart cells to uncover the genetic changes caused by the drug.
- Their findings highlighted key genes linked to heart damage and concluded that clozapine causes harmful changes in heart cells, leading to structural alterations and impaired fat metabolism, ultimately resulting in ACM-like symptoms.
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis.
CNS Drugs
September 2024
Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
Article Synopsis
- - Clozapine-induced myocarditis (CIM) is a serious side effect of clozapine treatment for schizophrenia, requiring immediate discontinuation of the drug, which can negatively affect patients' mental health and long-term outcomes.
- - There is growing interest in safely reintroducing clozapine after CIM, with a reported success rate of around 60%, yet research and case reports on this re-challenge process are still limited.
- - The review covers CIM's epidemiology, risks, and management, recommending cautious re-challenge strategies that involve slow dose increases and monitoring key biomarkers to prevent recurrence and ensure patient safety.
Reply to "Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter Region of Australia".
Schizophr Res
May 2024
Psychiatric Rehabilitation Service Hunter New England Mental Health Morisset, NSW 2264, Australia.
Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia.
Schizophr Res
May 2024
Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan; Department of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.
Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia.
Psychiatry Res
April 2024
Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan; Department of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.
During clozapine initiation, titration speed and concomitant valproate administration have been reported as risk factors for clozapine-induced fever and myocarditis. We tested the risk of concomitant valproate administration by stratifying patients according to titration rate. Concomitant valproate use was only associated with increased inflammatory adverse events in the slower titration group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!